Related Experiment Video

Updated: Nov 18, 2025

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
07:02

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

7.6K

BGL3 inhibits papillary thyroid carcinoma progression via regulating PTEN stability

M Zhao1, F Yang2, C Sang1

  • 1Department of General Surgery, Yanqing District Hospital, Beijing and Yanqing Hospital, Peking University Third Hospital, Beijing, People's Republic of China.

Journal of Endocrinological Investigation
|February 5, 2021
PubMed
Abstract

Insights

The long non-coding RNA BGL3 inhibits papillary thyroid carcinoma (PTC) progression by stabilizing PTEN. Reduced BGL3 levels correlate with advanced PTC, suggesting its potential as a therapeutic target and prognostic biomarker.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Papillary thyroid carcinoma (PTC) is a common endocrine malignancy.
  • Long non-coding RNAs (lncRNAs) are increasingly recognized for their roles in cancer.
  • The specific function of BGL3 in PTC remains uninvestigated.

Purpose of the Study:

  • To elucidate the clinical significance and biological function of BGL3 in human PTC.
  • To explore BGL3 as a potential diagnostic or therapeutic target for PTC.

Main Methods:

  • Quantitative real-time polymerase chain reaction (qRT-PCR) to assess BGL3 expression in 85 PTC and normal tissue pairs.
  • In vitro assays (CCK-8, colony formation, EdU, wound healing) to evaluate BGL3's effects on PTC cell behavior.
  • Mechanistic studies including ChIP, Co-IP, RNA pull-down, and luciferase reporter assays.
  • In vivo xenograft models in nude mice to assess BGL3's impact on tumor growth and metastasis.

Main Results:

  • BGL3 expression was significantly downregulated in PTC tissues compared to normal tissues, repressed by the oncogene Myc.
  • Lower BGL3 levels were associated with larger tumor size, lymph node metastasis, advanced TNM stage, and poorer prognosis.
  • Overexpression of BGL3 suppressed PTC cell proliferation and migration in vitro and reduced tumor size and lung metastasis in vivo.
  • BGL3 interacts with PTEN in the cytoplasm, enhancing OTUD3-mediated de-ubiquitination of PTEN, thereby increasing PTEN stability and inhibiting the PI3K/AKT signaling pathway.

Conclusions:

  • BGL3 plays a critical tumor-suppressive role in PTC through post-translational regulation of PTEN protein stability.
  • BGL3 demonstrates potential as a novel therapeutic target and prognostic biomarker for human PTC.
Keywords:
BGL3PTEN stabilityPapillary thyroid carcinoma (PTC)Prognosis

More Related Videos

Identification of Intracellular Signaling Events Induced in Viable Cells by Interaction with Neighboring Cells Undergoing Apoptotic Cell Death09:18

Identification of Intracellular Signaling Events Induced in Viable Cells by Interaction with Neighboring Cells Undergoing Apoptotic Cell Death

Published on: December 27, 2016

8.9K
Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors08:45

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

6.4K

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.9K
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
37.4K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
4.7K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.3K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.1K
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
8.5K